Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-Nitroindazole-2-carboxamidine is a synthetic small molecule belonging to the indazole class of organic compounds. It acts as an inhibitor of nitric oxide synthase, particularly endothelial nitric oxide synthase (NOS3). By binding at the substrate site of NOS, it disrupts normal enzyme function and inhibits the production of nitric oxide (NO), a key signaling molecule involved in vascular tone and neurotransmission. The compound has been studied structurally in complex with NOS enzymes and is considered experimental, with no approved medical indications or clinical trial activity reported. Its primary research interest lies in its potential neuroprotective effects via modulation of NO signaling pathways[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-nitroindazole-2-carboxamidine.